Understanding PAD.

Slides:

Advertisements

Similar presentations

PAD Rehabilitation Toolkit A Guide for Healthcare Professionals Healthy Steps for Peripheral Artery Disease (PAD) Developed by AACVPR and the Vascular.

Advertisements

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.

Dharam J. Kumbhani, MD, SM, MRCP, Ph. Gabriel Steg, MD, Christopher P. Cannon, MD, Kim A Eagle, MD, Sidney C. Smith, Jr., MD, Shinya Goto, MD, Cannon,

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Preventative medical practices in patients with vascular occlusive disease at Royal Perth Hospital Lip Gen Teh MBBS Kishore Sieunarine MBBS FRCSE FRACS.

Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.

Medical Management of Claudication: Just Walk it Off!!

Antithrombotic Therapy in Peripheral Artery Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.

Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Peripheral Artery Disease: Evolving Role of Exercise,

Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease Debbie C. Chen1, Gagan.

Rivaroxaban in stable peripheral or carotid artery disease

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

Anticoagulation after peripheral Vascular Intervention

Antithrombotic Therapy in Peripheral Artery Disease

High Hemoglobin A1c Associated with Increased Adverse Limb Events in Peripheral Arterial Disease Patients Undergoing Revascularization Shipra Arya, Zachary.

LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice.

First time a CETP inhibitor shows reduction of serious CV events

Medical Therapy for Peripheral Artery Disease

An Endocrinology Clinic in Dyslipidemia

Program Goals Teriflunomide: Pooled Safety Data.

Advances in Managing Inhibitors in Patients With Hemophilia A

NOACs, AF, and PCI: What Do the Latest Data Suggest?

When Is Adding Aspirin to NOACs Worth the Risk?

Heart Rate, HF Admissions, and Readmissions

Progression After Cancer Immunotherapy in Advanced NSCLC

PAD Patients vs Post-ACS Patients:

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Unmet Needs in the Secondary Prevention in ACS

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Successful Obesity Management and Counseling:

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

How and When to Decide on Revascularization in Stable Ischemic Heart Disease.

Recurrent Angina: New Tools for an Old Problem

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Watching for the Patient With AF: Latest Advances and Technologies

Gene Therapy: Past, Present, and Future

OTC NSAID Use in Patients With OA and CV Disease

Risk Stratification in CAD and PAD

Evaluating New Therapies in HF

Immunotherapy for cSCC

Advancing the Treatment of IBD With Biologics

Quantitating the Dose of Physical Activity in Secondary Prevention: Relation of Exercise Intensity to Survival Barry A. Franklin, PhD Mayo Clinic Proceedings

Exercise-Based Cardiac Rehabilitation and Improvements in Cardiorespiratory Fitness: Implications Regarding Patient Benefit Barry A. Franklin, PhD Mayo.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Factor Xa Inhibitors in PAD

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

CAD/PAD in Primary Care

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

The Burden of Psoriasis:

Patient Questions and Expert Answers in Psoriasis:

Antithrombotic Therapy in PAD

Latest Perspectives in PAD: How to Improve Outcomes

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Antithrombotics in Arterial Disease: Focus on Coronary Disease

How to Optimize Cholesterol Management in High-Risk CV Patients

Factor Xa Inhibitors in Coronary Artery Disease

Prioritizing Prevention of HPV-Related Disease

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Reassessing Risk Stratification in CAD/PAD

Emily Spangler, Robert W. Chang, Philip P. Goodney

PCSK9 Inhibitors and Real-World Evidence

Multimodal Approaches to Cracking the Code in Low Back Pain

Translating Data From Trial to Practice

Presentation transcript:

Understanding PAD

Goals

Peripheral Arterial Disease

Outcomes in Patients With Symptomatic PAD

Risk Factors for PAD

Physical Findings in PAD

Noninvasive Physiologic Tests for PAD

PAD Risk-Reduction Therapies

Exercise in PAD

Pharmacotherapy for Claudication FDA-Approved Drugs

Indications for Revascularization

Latest Advances in Pharmacotherapy

Vorapaxar -- Efficacy at 3 Years MI or PAD (No Stroke/TIA)

Vorapaxar and Limb Vascular Efficacy

Adverse Limb Events Prevention

Ongoing Investigation of Antithrombotics in PAD

Underused Available Therapies

Summary

Abbreviations

Abbreviations (cont)